Dishman Pharmaceuticals and Chemicals’ board has approved the proposal to issue non-convertible debentures (NCDs) up to an amount of Rs 75 crore, for augmenting medium to long-term resources of the company, including regular capital expenditure. Dishman Pharmaceuticals is engaged in manufacturing of Bulk APIs, Intermediates, Specialties and Quats.
You may also like
{ 1 comment }